Twist Bioscience Corp

Twist Bioscience Corp(TWST)股票分析

$132.060

-6.590 (-4.99%)收盤時

Loading chart…
High
138.150
Open
134.940
VWAP
133.74
Vol
1.28M
Mkt Cap
2.76B
Low
131.000
Amount
170.66M
EV/EBITDA, TTM
-65.25

Twist Bioscience Corporation provides customizable solutions across the biological continuum that enable scientific discovery and development across therapeutics, diagnostics, and other high-growth markets. The Company's proprietary silicon-based platform delivers precision, scale, and speed, supporting consistent, high-quality performance across a range of applications. The Company’s platform is a differentiated method of manufacturing synthetic deoxyribonucleic acid (DNA) by writing DNA on a silicon chip. By integrating proprietary hardware, software, and scalable infrastructure, including its e-commerce platform. The Company has extended this platform beyond DNA synthesis to offer an integrated portfolio that includes synthetic genes, next-generation sequencing, applications, sample preparation tools, antibody libraries, and biologic discovery services. Leveraging the same platform, it also manufactures synthetic ribonucleic acid (RNA) and expresses antibody proteins.

AI analysis of Twist Bioscience Corp (TWST)

buy

Twist Bioscience Corp is a good buy right now due to its current price of $141.38 being significantly lower than the analyst price target of $115, indicating potential upside. The company also shows a strong gross margin of 52.76% and has experienced a remarkable year-to-date change of +336.49%. However, the main risk is its negative earnings per share (EPS) of -0.56, indicating ongoing losses.

Analyst Ratings (3)

-68.76% downside
Buy
2 Buy
1 Hold
0 Sell
Current: 132.06
最低
39.00
平均
41.25
最高
43.00

Piper Sandler

2026-08-05

目標價

$115

Overweight

Baird

2026-08-04

目標價

$115

Outperform

TD Cowen

2026-08-03

目標價

$115

Buy

Canaccord

2026-07-14

目標價

$120

Buy

Evercore ISI

2026-07-06

目標價

$102

In Line

估值指標

The current forward P/E ratio for Twist Bioscience Corp (TWST) is 0.00, compared to its 5-year average forward P/E of -13.67.

Forward P/E

Overvalued
5Y Average P/E
-13.67
Current P/E
0.00
高估
-6.49
低估
-20.85

Forward EV/EBITDA

Strongly Undervalued
5Y Average EV/EBITDA
-17.58
Current EV/EBITDA
-65.25
高估
-5.44
低估
-29.72

Forward P/S

Overvalued
5Y Average P/S
8.24
Current P/S
16.97
高估
14.29
低估
2.19

Alphio AI Price Scenarios for TWST

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%TWST

$42.17

情境價格

B

Base

Base · 50%TWST

$34.59

情境價格

B

Bear

Bear · 25%TWST

$32.47

情境價格

Whales holding TWST

G

Granahan Investment Management, LLC

+ HoldingTWST

+11.84%

3M Return

P

Peregrine Capital Management, LLC

+ HoldingTWST

+6.83%

3M Return

E

EdgePoint Investment Group Inc.

+ HoldingTWST

+5.44%

3M Return

A

ARK Investment Management LLC

+ HoldingTWST

+3.60%

3M Return

W

William Blair Investment Management, LLC

+ HoldingTWST

+1.88%

3M Return

T

Tao Capital Management LP

+ HoldingTWST

-1.17%

3M Return

事件時間軸

2026-08-27 (ET)

12:00:00

SoftBank Plans Up to $20B Bond Offering for Refinancing

2026-08-05 (ET)

06:30:00

Deal Size Increased to $300M

2026-08-04 (ET)

08:30:00

Twist Bioscience Grants 44,434 RSUs to 24 New Hires

2026-08-03 (ET)

07:30:00

Company Reports Q3 Revenue of $118.4M, Exceeding Expectations

2026-06-18 (ET)

16:30:00

Twist Bioscience Files Automatic Mixed Securities Shelf

資訊

TWST FAQ — answered by Alphio AI

Twist Bioscience Corporation provides customizable solutions across the biological continuum that enable scientific discovery and development across therapeutics, diagnostics, and other high-growth markets. The Company's proprietary silicon-based platform delivers precision, scale, and speed, supporting consistent, high-quality performance across a range of applications. The Company’s platform is a differentiated method of manufacturing synthetic deoxyribonucleic acid (DNA) by writing DNA on a silicon chip. By integrating proprietary hardware, software, and scalable infrastructure, including its e-commerce platform. The Company has extended this platform beyond DNA synthesis to offer an integrated portfolio that includes synthetic genes, next-generation sequencing, applications, sample preparation tools, antibody libraries, and biologic discovery services. Leveraging the same platform, it also manufactures synthetic ribonucleic acid (RNA) and expresses antibody proteins. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

Twist Bioscience Corp is a good buy right now due to its current price of $141.38 being significantly lower than the analyst price target of $115, indicating potential upside. The company also shows a strong gross margin of 52.76% and has experienced a remarkable year-to-date change of +336.49%. However, the main risk is its negative earnings per share (EPS) of -0.56, indicating ongoing losses.

3 analysts cover TWST: 2 rate it Buy, 1 Hold and 0 Sell. The average price target is 41.25.

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

免費開始